Medivir and Cancer Research Technology collaborate to

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Apr 13, 2015 at 2:45 AM

Medivir and Cancer Research Technology collaborate to develop new class of cancer drugs

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) and Cancer Research Technology (CRT), Cancer Research UK’s commercialization and development arm, today jointly announce a partnership to develop a new class of drugs that has shown promise for treating a range of different cancers, including pancreatic cancer. As part of the collaboration, CRT and Medivir will conduct a two-year research programme to optimize and develop small molecules targeting the cell surface protein ADAM8, which has been linked to tumour survival, cell invasion and metastasis. Under the terms of the agreement Medivir receives an exclusive, global license to research, develop, manufacture and commercialize ADAM8 inhibitor drugs resulting from development. CRT receives an upfront payment and future success milestones as well as royalties on sales which are shared with the academic collaborators. Blocking ADAM8 in mice with pancreatic cancer prevented the spread of the disease, shrunk tumours and significantly extended lifespan. This is thought to be due to its involvement in cell adhesion, cell migration, inflammation and the growth of blood vessels – key processes that many cancers rely on for growth and development. High levels of the protein have been linked with more aggressive tumours including those in pancreatic, breast, brain, prostate, lung, head and neck, and kidney cancers. This research will be led by Professor Jörg Bartsch as head of the TransMIT -Project Division for Research in Neuro-Oncology at TransMIT GmbH, located at Marburg University in Germany, in collaboration with Medivir. Prof. Bartsch previously worked at King’s College London where the initial patent application was filed by King’s College IP and Licensing team. Further proof of concept studies were funded by Cancer Research UK at King’s College. “We are very glad and excited to see this collaboration come to life. The synergy of expertise between Medivir and our Laboratory forms an excellent platform for successful exploration of this first-in-class approach to targeted therapy against ADAM8. This really is “bench-to bedside” research at its best,” said Professor Bartsch. “This collaboration is a demonstration of our commitment to advance oncology drug discovery at Medivir and we are pleased to partner with such a renowned institution such as Cancer Research UK, and with Professor Bartsch, a leading researcher in the field,” said Niklas Prager, Medivir’s CEO. Dr Keith Blundy, Cancer Research Technology’s chief executive officer, continues: “Medivir’s significant expertise in protease inhibitor design coupled with CRT’s proven track record in drug development will hopefully pave the way for an exciting new class of drugs for treating cancer. Exploratory studies indicate that ADAM8 is an attractive target across many types of cancer, and potentially other diseases driven by inflammation, and we look forward to further exploring that promise through this innovative collaboration.” For further information, please contact: Ola Burmark, CFO Medivir AB, mobil: +46 (0)725-480 580. Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 08.30 CET on 13 April 2015. About Medivir Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List. About Cancer Research Technology Cancer Research Technology (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is a wholly owned subsidiary of Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research. Further information about CRT can be found at www.cancertechnology.com. About Cancer Research UK Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research. Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives. Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated. Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last forty years. Today, 2 in 4 people survive cancer. Cancer Research UK’s ambition is to accelerate progress so that 3 in 4 people will survive cancer within the next 20 years. Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses. Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured. For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tellus Raises APY to 8.00% Amid Inflation Crunch

Tellus Offers a Boost for Savers Battling Inflation Well, hotshot, if you thought the days of high returns on savings were long gone, tell that to Tellus. This proptech outfit just upped its Reserve Account annual percentage yield (APY) to a juicy 8.00%. That's a damn sight better than the pittance you'll get parking funds elsewhere. Just look at the numbers—consumer...

Aviation Expo Draws Crowds, Revitalizing Future Pilots

Youth Flock to Aviation's Future at Rider Jet Center On a crisp November day in Hagerstown, Maryland, the Rider Jet Center became a hive of ambition and dreams as the 20th Aviation Education & Career Expo unfolded. The whole shebang kicked off like an airport on a holiday weekend, bustling and packed. Over 1,100 students—full of questions, hopes, and the typical teen...

Deadline Nears for Everest Group Class Action Plaintiffs

Everest Group Faces Heavy Litigation Alright, folks, grab your mugs of caffeine and let's dive right into the mess Everest Group, Ltd. has found itself in. The clock is ticking for investors who've taken a punch in the gut between February 8, 2024, and October 27, 2025, courtesy of NYSE: EG. Lawyers are on the chase, and come December 28, 2026, the window to spearhead a...

Qfin Faces Class Action Deadline Amid Regulatory Woes

Hit the Deck: Qfin's Legal Storm Brews When the suits begin to rumble, it’s high time to pull up a seat and watch how these chips fall. If you're parking your funds under NASDAQ:QFIN—heads up! A shareholder rights firm is bringing a class-action lawsuit, and investors perched between March 18 and August 25, 2026, should be ready to jump ship or fight. The Mighty...

Poolwerx Expands in Florida: Matt Feldt's Bold Move

A New Wave in Northeast Florida Bet you didn't expect to hear about pool care while sipping your morning coffee, but here we are. Poolwerx, the heavyweight champion in the pool service world, is pumping up its presence in the Northeast Florida landscape. Guess who’s the man behind this expansion? Matt Feldt, a Navy vet who’s traded in sonar for skimmers, has opened...

Wastewater Treatment Market to Hit $99.56B by 2031

The Changing Face of Wastewater Treatment Here's a whopper to chew on: the wastewater treatment services market ain't your grandfather's playground anymore. No sir, it's a fast-evolving arena aiming to swell to a whopping USD 99.56 billion by 2031. Now, how's that for growth? Mark my words, driven by stringent environmental regulations and thirst for clean water, this...

AI Governance: Banks' Secret to Successful Scaling

AI in Banking: Cautious Steps Forward Banks aren't exactly racing with AI; they're inching forward. With AI agents entering the picture, you'd think the buzz would be about groundbreaking deployments. Instead, the story here is more about banks holding their cards close to the vest. Agentic AI, with its ability to plan and act without a human babysitter at every step, is...

Global Youth Co-Creation Plan Inspires Deep Living

Rediscovering Authenticity in a Fast-Paced World In a world obsessed with snappy content and instant fame, it's refreshing to see an initiative like the Global Youth Image Co-creation Plan take center stage. Unveiled at the third Hong Kong Night, the plan isn't just another flash in the pan. No, it's a call—practically a rallying cry—for young creators worldwide to...

POWERCHINA's Clean Energy Initiatives at COP31 Spotlighted

A Global Push for Clean Energy: POWERCHINA's Role Picture this: a bustling global scene at the United Nations Climate Change Conference, COP31, in Antalya, with leaders huddling over the future of our planet's energy. Meanwhile, Power Construction Corporation of China (POWERCHINA) is out there in the trenches, muscling through the monumental task of turning ambitious...

Lululemon Lawsuit Looms: Investors Face Key Decisions

Seems Lululemon just tripped on its yoga mat. When a company like Lululemon Athletica, Inc (NASDAQ:LULU) sees a 17.38% slide in stock, every savvy investor knows there's more beneath the surface. Squarely in the crosshairs of a securities fraud class action, the brand synonymous with upscale athleisure faces harsh scrutiny. And the deadline's ticking—even the suits know...